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Cyclen-based macrocyclic ligands have an essential role in the development of contrast agents for
magnetic resonance imaging (MRI). A prevailing need for preparation of multifunctional probes triggered
a number of attempts to synthesize and derivatize ligands which efﬁciently chelate lanthanide ions and
have advantageous MRI properties. This digest Letter summarizes the most common synthetic
approaches for the preparation of macrocyclic ligands based on cyclen depending on the desired
application.
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Magnetic resonance imaging (MRI) has become an important
tool in biomedical research and is an essential diagnostic method
in clinical radiology today. Moreover, the existence of different
types of MRI contrast mechanisms in tissues provides for continu-
ous development of this method.1 MRI enables tracking of physio-
logical changes noninvasively, allowing imaging of speciﬁc
biological processes at the molecular or cellular level. To further
improve the speciﬁcity of MRI, a number of contrast agents have
been developed and employed to date. According to their mecha-
nism of action, contrast agents suitable for 1H MRI can be classiﬁed
as T1- and T2-shortening agents or CEST agents.2 The vast majority
of them are based on lanthanide complexes with polyamino poly-carboxylic ligands. Due to better thermodynamic and kinetic sta-
bility properties that reduce the potential toxicity of the MRI
agents in vivo, multidentate macrocyclic chelators based on
1,4,7,10-tetra-azacyclododecane (cyclen) are the most commonly
used chelating agents nowadays,2 although their role in preparing
contrast agents for positron emission tomography (PET), single
photon emission computed tomography (SPECT), or optical imag-
ing is also very important.3,4
The extensive use of cyclen-based contrast agents demands
continuous improvements in derivatization and preparation of
novel macrocyclic molecules with various chelating and functional
groups. Synthetic changes aim to improve speciﬁc physicochemical
or biological properties of the contrast agents thereby enabling
their binding to particular macromolecules, localization to a spe-
ciﬁc organ or receptor and hence expanding the scope of their
application.5–7 To obtain various products with diverse desired
structures and properties, an awareness of the synthetic chemistry
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Figure 1. Structures of principal chelators described in this work.
760 N. Cakic´ et al. / Tetrahedron Letters 56 (2015) 759–765of these systems is required, especially of the numerous C- and N-
functionalization procedures of cyclen.
To this end, a number of review articles and books focused on
preparation, general chemical properties, or application of contrast
agents have been already published.1,2,8–13 In the present work, we
concisely summarize existing methodologies for the synthesis of
the most common macrocyclic chelators (cyclen-1,4,7,10-tetraace-
tic acid – DOTA, cyclen-1,4,7-triacetic acid – DO3A and cyclen-1,4-
or 1,7-diacetic acid – cis- or trans-DO2A, respectively, Fig. 1) and
their derivatives, emphasizing the most straightforward synthetic
pathways for their preparation. Furthermore, we discuss different
methodologies that lead to functionalization of the cyclen pendant
arms. Finally, we brieﬂy list some recent examples of contrast
agents that were prepared according to such procedures, ﬁnding
useful applications.
Ligands based on DOTA
DOTA is an octadentate ligand with four carboxylate and four
amino groups which coordinate with lanthanide ions. Conse-
quently, their complexes with DOTA possess high thermodynamic
stability and kinetic inertness, making these compounds useful in
MRI as contrast agents. DOTA can be easily prepared by tetra N-
alkylation of cyclen with chloroacetic acid. This synthetic proce-
dure was reported almost four decades ago and is still an accept-
able method for DOTA preparation (Scheme 1).14 Other
haloacetic acid derivatives (bromo- or iodo-) can also be used as
alkylating agents, and such a procedure is especially useful for
the preparation of the tetraamide (DOTAM) chelators. Here the
common precursor is chloroacetyl chloride which is ﬁrst converted
to the desired chloroacetamide; subsequently the conversion of
chloro- to iodoacetamide is done prior to alkylation (Scheme 1),15
resulting in numerous compounds that are suitable for use as con-
trast agents for CEST MRI.16,17
A number of procedures for preparation of DOTA derivatives
exist to date, resulting in products that can be divided into two
general groups: (a) N-functionalized and (b) C-functionalizedHN
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Scheme 1. General synthetic scheme for the preparation of DOTA (top) and
DOTAM-type chelators (bottom) from cyclen. The most common conditions are: (i)
XCH2COOH or (ii) XCH2CONHR (X = Cl, Br, I), DIPEA or K2CO3, MeCN or DMF. R
stands for hydrogen, an alkyl or an aryl group.DOTA-type ligands. The former can be prepared starting from the
monoalkylation of cyclen with one group, followed by the alkyl-
ation of the remaining three secondary amine positions with
another group (Scheme 2, route 1). The second approach for N-
functionalized DOTA ligand synthesis includes alkylation of the
remaining amine on the ester-protected DO3A-type ligand
(Scheme 2, route 2), which easily reacts with various alkyl halides
in aprotic solvents. These two procedures will be described in more
detail in the next section (see below). Older procedures to prepare
N-functionalized DOTA derivatives involve the use of acyclic pre-
cursors and 2+2, 3+1 or 4+0 cyclization processes.11 However,
these procedures are no longer the most convenient, given the
wide commercial availability of cyclen as the essential starting
material in all procedures.
C-functionalized DOTA-type ligands can be prepared by intra-
molecular or intermolecular cyclization methods using appropriate
scaffolds. For instance, the intramolecular cyclization of tosyl
amide (prepared from tetrapeptide followed by borane reduction
and tosylation) at high dilution and subsequent detosylation with
a concentrated strong acid results in C-functionalized cyclen.18 Its
alkylation with tert-butyl bromoacetate, followed by hydrolysis
yields a C-functionalized DOTA-type ligand 1 (Scheme 3, route 1).
This synthesis has been improved by initiating the cyclization of
diamine with carbamate-protected disuccinimido ester at high-
dilution at a higher temperature (90 C) (Scheme 3, route 2).19
Using these synthetic approaches, a number of different C-func-
tionalized DOTA can be prepared by a simple variation of side
arm (R0).
In general, because preparation of N-functionalized DOTA deriv-
atives is much more convenient, they are the more frequently used
ligands. One of the ﬁrst DOTA bifunctional chelators 2 was devel-
oped for protein and antibody labeling (Fig. 2). The synthetic
approach to obtain 2 includes side arm transformation following
the strategy from Scheme 2 (route 1). The initial precursor contains
a p-nitrophenyl group, which is then transformed to isothiocya-
nate, allowing further synthetic transformations and coupling
reactions with primary amines.20 Following a similar synthetic
strategy, N-functionalized DOTA derivatives with self-immolative
arms as potential enzyme-responsive MRI contrast agents were
reported (3, Fig. 2).21 Recently, a range of building blocks for the
preparation of DOTA-like chelating agents was also prepared. The
procedure starts from DOTAGA-anhydride (GA = glutaric acid)
which can be selectively opened with different nucleophiles,
resulting in a variety of bifunctionalized DOTA derivatives of type
4 (Fig. 2).22 This kind of ligand is useful for both in vitro and
in vivo applications. For instance, the reactive moiety of these
DOTA-type chelators allows further coupling procedures andN
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Scheme 2. Synthetic routes for the preparation of N-functionalized DOTA ligands.
The most common reagents: (ia) BrCH2COOR0 , K2CO3/MeCN; (ib) RCH(X)COOR0 ,
K2CO3 or Et3N/MeCN or DMF; (ii) HCl/MeOH, HCOOH or TFA (for R0 = tBu), or LiOH,
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Figure 2. Some examples of N- and C-functionalized DOTA derivatives.
N. Cakic´ et al. / Tetrahedron Letters 56 (2015) 759–765 761preparation of high molecular weight MRI contrast agents. Such
agents have high relaxivity and long half-lives in the circulation,
which is very advantageous for MRI applications.23 For example,
polyamidoamine (PAMAM) or polylysine (Gadomer) dendrimeric
contrast agents can be prepared in this manner, carrying large
numbers of monomeric DOTA-type units, and hence amplifying
the MRI signal.24,25 C-functionalized DOTA derivatives with isothi-
ocyanate pendant arms (5, Fig. 2) can be used for the same pur-
pose, to react with the terminal amino groups of the dendrimer,
providing high molecular weight contrast agents of different den-
drimer generations (G4-6).26
Ligands based on DO3A
As well as DOTA, DO3A is also a compound of great importance
for MR imaging. This heptadentate ligand possesses one fewer car-
boxylic group for chelating lanthanide ions, but has a secondaryNH HN
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Scheme 4. The most common routes (1–3) for the synthesis of DO3A derivatives (left)
reagents: (i) BrCH2COR, K2CO3/MeCN; (ii) R0X, K2CO3 or Et3N/MeCN or DMF; (iii) Boc
substituents. Cleavage reagents for deprotection: NaOH or KOH in H2O (for 7, 9 and 12);
MeCN (for 11).amine in the cyclen ring available for a number of synthetic trans-
formations. It therefore represents a suitable scaffold and one of
the most commonly used precursors for the preparation of a vari-
ety of macrocyclic chelates. DO3A can be easily transformed to an
octadentate ligand by different derivatization reactions to yield
various bifunctional, targeted, or responsive (smart) contrast
agents.2,9 In this way, these molecules can also be converted to
DOTA derivatives with one functionalized arm (see above),
employing similar synthetic pathways for obtaining typical DO3A
derivatives, which we describe in this section.
The most straightforward and commonly used synthetic route
for the preparation of DO3A-type ligands is direct and selective
alkylation of the three secondary amine positions in the cyclen
(Scheme 4, route 1). Depending on the need for further DO3A mod-
iﬁcations, electrophiles with acid-labile (the most commonly tert-
butyl),27 or base-labile (methyl or ethyl) esters can be used.28
The products thus obtained (tert-butyl, ethyl or methyl esters of
DO3A) easily react further with a range of alkylation agents result-
ing in a range of functionalized ligands of type 6 (Scheme 4, route
1). Moreover, the hydrolysis of esters is usually mild and fairly
clean, resulting in convenient preparation of the desired DO3A
derivative. It is of note that tris-tBu-DO3A is probably the most
widely used precursor among these derivatives today; it is com-
mercially available, and its preparation is also quite convenient
and easy.27
The same route 1 (Scheme 4) is also very suitable for the
synthesis of amide derivatives of DO3A using previously prepared
amide-containing electrophiles.29 Different reaction conditions
and inﬂuences of the chosen electrophiles on three- or tetra-
substituted cyclen with arginine pendant groups were recently
studied.30 For instance, the usage of iodo-derived electrophiles
favored the formation of DO3A-type, while the DOTA-type
products predominated when chloro-derived electrophiles were
used. This study indicates that the choice of the electrophiles is
an important step for the controlled synthesis of functionalized
DO3A/DOTA-type ligands.N
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functionalized molecules is the direct cyclen monoalkylation
(Scheme 4, route 2), followed by substitution of the remaining
three amine positions with tert-butyl bromoacetate or other elec-
trophiles. A number of mono N-alkylated products with a range
of alkylating agents were prepared using this strategy and mild
conditions.31 More recently, a monoalkylation procedure using a
four-fold excess of cyclen was described where the unreacted
cyclen can be successfully recovered. Depending on the alkyl
halides used, moderate to good yields were obtained; the ﬁnal
products were isolated without puriﬁcation by column chromatog-
raphy.32 Various further reaction conditions exist to obtain
different N-monofunctionalized cyclens. These include further
alkylation, acylation, sulfonylalkylation or sulfonylarylation proce-
dures.11 Mono-amide cyclen derivatives can be also prepared in
such a manner.33 The drawback of these procedures is the possibil-
ity of side product formation, thus requiring column chromatogra-
phy puriﬁcation of the obtained product.34
Although this strategy appears to be easy and straightforward
for the synthesis of various functionalized cyclen-type contrast
agents, it is actually not widely used. Reasons for this could be
the bis- and tris-substituted byproduct formation which compli-
cates isolation of the desired product. In such cases, when the syn-
thetic route is more demanding or direct alkylation methods are
not suitable for the preparation of the targeted molecule, a slightly
modiﬁed strategy can be followed. It involves protection of three
cyclen amines with Boc groups, followed by alkylation of the
fourth position with terminally functionalized electrophile. After
Boc deprotection under mild acidic conditions, various carboxylic
acid derivatives can be introduced into the molecule with this
strategy (Scheme 4, route 3).35 The disadvantage of this route is a
need to prepare tris-Boc-cyclen,36 and a limited choice of electro-
philes. Namely, in the majority of cases, tris-Boc-cyclen alkylation
with halides is not optimal most likely due to sterical constraints
and therefore a better option for alkylation is reductive
amination.37
Along with Boc, different protected cyclens can be used as inter-
mediates (Scheme 4): cyclen–glyoxal bis-aminal (7),38 cyclen–tri-
carbonylmolybdenum (8),39 triheterocycles borane derivative
(9),40 orthoamide (tricycloderivative—10),41 tritosylated cyclen
(11),41 triformylcyclen (12),42 or phosphoryl species.43 The proce-
dures involving these protected cyclens usually include multistep
reactions and were summarized in a recent review article.11
Once DO3A derivatives or DO3A precursors with appropriate
protecting groups have been prepared, further synthetic transfor-
mations can be performed to yield the desired so-called bifunc-
tional agents, these products may be used for lanthanides
complexation and MRI contrast agent preparation. In general, there
are two distinct methods for the synthesis of bifunctional contrast
agents (Scheme 5). These include either further functionalization
of one of the DOTA carboxylic groups (usually accomplished by
conversion into various amide derivatives), or a direct monoalkyla-
tion of cyclen or tris-protected DO3A with an a-halogenated mol-
ecule. For instance, a terminally positioned amino group can beN N
HNN
R= -CN,-NHCbz or Phd; usually n=1-3
N N
NN
n
NH2
N N
NN
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iia-c i
Scheme 5. The most convenient strategies for preparation of the bifunctional DO3A deri
K2CO3/MeCN; (iia) H2, Pd/C, EtOH (for NHCbz or COOBn); (iib) H2, Raney-nickel, NaOH, EtO
diverse substituents.introduced to DO3A, protected as Cbz carbamate or phthalimide.
A primary amine suitable for further synthetic modiﬁcations is
subsequently obtained using mild deprotection conditions.44,45
Alternatively, a pendant arm with a terminal nitrile group can be
introduced into the molecule. Upon nitrile reduction in a hydrogen
atmosphere using Raney-nickel as a catalyst, an amine-containing
DO3A precursor can be obtained to serve as a precursor for the syn-
thesis of the bismacrocyclic chelators.35 On the other hand, a car-
boxylic group on the pendant arm that is suitable for further
functionalization can be introduced in a similar fashion as Bn-
ester. Subsequently, the free acid will be obtained upon the Pd/C-
catalyzed hydrogenation.46 Overall, the reductive reactions dis-
cussed in this paragraph are good solutions for performing the nec-
essary synthetic transformations on DO3A derivatives. Namely, the
presence of multiple acid- or base-labile protecting groups on the
DO3A (see above) limits the possibilities to conduct further trans-
formations. Therefore, reactions under neutral conditions (i.e.,
reductions) appear to be a good solution in such cases.
Azide-functionalised DO3A derivatives can also serve as useful
compounds with activated side arms. Recently, these kinds of com-
pounds were reported to link two kinetically stable metal com-
plexes together,34 or to link a chromophore to lanthanide
complexes via CuI-catalyzed ‘click’ 1,3-dipolar azide–alkyne cyc-
loadditions (Scheme 6).47 It should be noted that unmetallated
cyclen-based scaffolds should not undergo ‘click’ cyclizations due
to Cu+-sequestration by the macrocycle. It is therefore necessary
to ﬁrst prepare the desired lanthanide complex with azide- or
alkyne-appended DO3A or DOTA before performing the ‘click’
reaction.47
It is worth to note that isolation and puriﬁcation of majority of
these compounds appears to be one of the main challenges
throughout their synthesis. Most commonly, the protected ligands
are puriﬁed by column chromatography on silica gel using polar
eluent systems combined from CH2Cl2 or CHCl3 with MeOH or
EtOH, in occasional cases with addition of NH4OH or Et3N
(few%).20,36–38,48 Less polar intermediates can sometimes be eluted
with combination of ethyl acetate with hexane or dichloromethane.N N
NN
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chelators are formed, an HPLC on reverse phase C18 columns is per-
formed, using water and acetonitrile or methanol as eluents.22,38,45
Occasionally after the reaction work-up is done in acid or based
medium, the puriﬁcation can be performed using strong or weak
cation or anion exchange resins.49,50 Finally, different crystallization
techniques using appropriate combination of solvents can be used
for compound isolation in very speciﬁc cases.37,46
A methodology which can dramatically reduce number of
tedious puriﬁcation steps mentioned above is the synthesis on
solid support. This synthetic strategy was indeed used to obtain
bifunctional DO3A-peptide conjugates. It mainly involves coupling
tris-tBu-DO3A to the N-terminus of peptides bound on the polymer
resin. In the same manner, tris-allyl-, tris-methyl- or tris-benzyl-
DO3A esters can be employed. It is important to note that protect-
ing groups on the DO3A derivatives used have to be compatible
with the solid phase synthesis conditions. A range of DOTA-peptide
conjugates have been synthesized and investigated up to now.51
The abovementioned methods described for preparation of var-
ious DO3A functionalized compounds list just the most commonly
used strategies for preparation of potentially useful MRI contrast
agents. A number of further bifunctional DO3A derivatives
obtained via the introduction of different pendant arms have also
been reported (Fig. 3). Mono- and bis(phosphonate)-containing
ligand 13 showed potential as a positive MRI contrast agent for
bone and other calciﬁed tissues.52 The molecule 14 bearing a pen-
dant diphenylphosphinamide moiety enables non-covalent bind-
ing to human serum albumin,49 while molecules of type 15 with
an aryl phosphonate group can serve as bimodal (optical and MR
imaging) agents.53 The ligand 16 represents a PARACEST agent
investigated for its potential for labeling adenovirus particles,50
while compound 17 has been developed as a responsive MR con-
trast agent for selective copper sensing.48 Listing all the procedures
and applications of contrast agents thus obtained is beyond the
scope of this work; however, a number of recent review articles
that deal with these topics can be found for further reading.8,9,54,55
Ligands based on DO2A
This cyclen derivative allows immediate synthetic transforma-
tions on two secondary amines on the macrocyclic rim. DO2A
possesses two acetic arms which chelate lanthanide ions and can
be either at position 1,4 (N-cis) or 1,7 (N-trans). Nevertheless, thethermodynamic and kinetic stability of lanthanide complexes with
DO2A is too low for further in vivo studies due to an insufﬁcient
number of coordination bonds between the DO2A chelator and
the lanthanide ion (coordination number 6: four amines in the
cyclen ring and two carboxylic acids). Therefore, DO2A is mainly
used as a precursor for preparation of multifunctional contrast
agents, and not as a ﬁnal chelator for preparation of the lanthanide
complexes and their use in MRI.
Up to now several different approaches for the double function-
alization of cyclen were reported. Although direct derivatization is
convenient for preparation of tri- or tetra-substituted cyclen (see
above), this approach exhibits lack of regioselectivity in the case
of di-substituted cyclen derivatives, resulting in a mixture of
mono-, di-, tri- and tetra-functionalized products. The most com-
monly accepted methodology for DO2A synthesis thus includes a
series of protection-functionalization-deprotection steps (Schemes
7 and 8, route 1). Principally, the initial steps involve reaction of
selective amine protection at trans- or cis-positions (1,4 or 1,7), fol-
lowed by alkylation of remaining two amines with suitable acetic
esters or amides. The ﬁnal stage involves the amine deprotection
and their further derivatization (usually alkylation). It is also pos-
sible to switch these two steps of alkylation by preparing 1,4- or
1,7-disupstituted alkyl- or aryl-cyclens that can be further trans-
formed into DO2A derivative in the second alkylation stage.11
Either of these synthetic strategies results ﬁnally in symmetrical
or unsymmetrical N-trans or N-cis DO2A derivatives (compounds
of type 18, Scheme 7 and type 19, Scheme 8).
Following these strategies, a selective N1,N7-difunctionaliza-
tion of cyclen can be achieved at high yield under acidic condition
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Figure 4. Structures of some symmetrical and unsymmetrical trans-DO2A based derivatives.
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duction of the undesired 1,4-substitution product, and allows the
preparation of various carbamate-protected amines by using a
range of chloroformates (methyl, ethyl, benzyl, or tert-butyl),
depending on the choice of conditions required for their removal.
The same regioselectivity can be achieved in nearly quantitative
yields when the corresponding (oxycarbonyloxy)succinimide
reagents are used as electrophiles.57 Very recently, a tBu-DO2A
ester was also prepared from these reagents, however in a rapid
manner using microwave-assisted hydrogenation.58 Finally, using
a completely different strategy, 1,7-cyclen derivatives can be pre-
pared from protected cyclen 7 (Scheme 4) upon reaction with a
number of alkyl-halogenides.59
On the other hand, a selective N1,N4-dialkylation of cyclen can
be achieved using diethyl-oxalate as a protecting group to yield
cyclenoxamides (Scheme 8, route 1). This intermediate can be fur-
ther alkylated with tert-butyl bromoacetate or other electrophiles.
Following the deprotection of the oxalate using a strong base, a cis-
disubstituted cyclen product can be obtained, which is then avail-
able for second alkylation.60
In addition to these described methodologies, procedures for
preparation of 1,4- or 1,7-DO2A that omit protection steps have
also been reported. Thus, 1,7-DO2A can be prepared by trans-
disulfomethylation of cyclen, followed by conversion of sulfonates
to cyanides which upon hydrolysis ﬁnally result in acetate groups
thereby forming the acetate moiety (Scheme 7, route 2).61 On the
other hand, the 1,4-isomer can be obtained upon alkylation of
cyclen with tert-butyl bromoacetate in chloroform at room tem-
perature in the presence of 10 equiv of triethylamine. After per-
forming ﬂash chromatography, the desired 1,4-disupstituted
cyclen derivative can be isolated with a good yield (Scheme 8,
route 2).62
Once the desired DO2A derivative has been prepared, it can
undergo further synthetic transformations sequentially on the
third and fourth secondary amine positions, or at both amines
simultaneously. For instance, its mono alkylation with the alpha-
halogenated protected carboxylic acid yields a functionalized
DO3A derivative. This can be further modiﬁed by alkylating the
fourth ‘free’ amine position on the cyclen ring to prepare biotinyl-
ated pH-responsive contrast agents that can interact with the pro-
tein avidin.63 This strategy appears to be much more convenient as
a similar bifunctionalized DO3A agent has also been reported
(although using a different preparation strategy that did not start
with a DO2A derivative), resulting in a much lower yield of the
desired product.64
Further examples of DO2A derivatives (mainly trans-variants)
that were prepared for use as MRI contrast agents have been sum-
marized recently.58 In most of cases, these include the symmetrical
bifunctionalized DO2A chelators that have the same group in the
trans position (in addition to two methylencarboxyl group).
However, asymmetrical derivatives with two different pendant
arms were also prepared (Fig. 4). For instance, although compound20 is a DOTA derivative, it can also be classiﬁed as a symmetrical
trans-DO2A agent according to the synthetic preparation pathway.
Its Eu-complex exhibits a CEST effect and can be potentially useful
as vascular MRI agent.65 The same goes for compound 21, belong-
ing in this case to asymmetrical trans-DO2A derivatives. It is
designed as an MRI agent with a potential to be a versatile tracer
for multimodal imaging.66 Additionally, responsive contrast agents
can also be prepared from DO2A derivatives: compounds 22 and 23
were used to prepare MRI agents sensitive to zinc and pH,
respectively.67,68
Conclusions
The recent expansion of different MRI methodologies has
resulted in an increased demand for MRI contrast agents. Among
these, a number of cyclen-based chelators such as DOTA, DO3A,
DO2A and their derivatives have been prepared thus far. The most
straightforward methodology for their synthesis is the direct alkyl-
ation of cyclen at the desired position. Nevertheless, due to lack of
selectivity in most cases, strategies that involve diverse chemis-
tries with protecting groups are required to obtain a product with
the appropriate functional groups. The chosen protecting groups
should be inert toward a wide range of reaction conditions and
susceptible to easy cleavage under mild reaction conditions, leav-
ing other functional groups in the chelator intact. Once these
requirements are fulﬁlled, further modiﬁcation of these chelators
in terms of pendant arm functionalization is leading to diversiﬁca-
tion of contrast agents with a number of improved physicochemi-
cal and biological properties. The brief summary of well-
established methods as well as also contemporary synthetic meth-
ods for the preparation of cyclen-based MRI contrast agents pro-
vided in this article should aid a better understanding of their
chemistry, as well as assist in more convenient preparation of
agents that are yet to be developed.
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